Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA neoadjuvant CAPOX-docetaxel plus atezolizumab in resectable gastric/GEJ adenocarcinoma
NL-OMON59224Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, docetaxel and atezolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and feasibility. Started Feb 2018; status: recruiting.
02
Drugs
capecitabineoxaliplatindocetaxelatezolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59224.